JP2017526716A5 - - Google Patents

Download PDF

Info

Publication number
JP2017526716A5
JP2017526716A5 JP2017513658A JP2017513658A JP2017526716A5 JP 2017526716 A5 JP2017526716 A5 JP 2017526716A5 JP 2017513658 A JP2017513658 A JP 2017513658A JP 2017513658 A JP2017513658 A JP 2017513658A JP 2017526716 A5 JP2017526716 A5 JP 2017526716A5
Authority
JP
Japan
Prior art keywords
group
formula
compound
pharmaceutically acceptable
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2017513658A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017526716A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2015/070449 external-priority patent/WO2016038007A1/en
Publication of JP2017526716A publication Critical patent/JP2017526716A/ja
Publication of JP2017526716A5 publication Critical patent/JP2017526716A5/ja
Ceased legal-status Critical Current

Links

JP2017513658A 2014-09-12 2015-09-08 カテプシンcのスピロ環状阻害剤 Ceased JP2017526716A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14184613 2014-09-12
EP14184613.9 2014-09-12
PCT/EP2015/070449 WO2016038007A1 (en) 2014-09-12 2015-09-08 Spirocyclic inhibitors of cathepsin c

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017246001A Division JP6360961B2 (ja) 2014-09-12 2017-12-22 カテプシンcのスピロ環状阻害剤

Publications (2)

Publication Number Publication Date
JP2017526716A JP2017526716A (ja) 2017-09-14
JP2017526716A5 true JP2017526716A5 (enExample) 2017-10-26

Family

ID=51535355

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017513658A Ceased JP2017526716A (ja) 2014-09-12 2015-09-08 カテプシンcのスピロ環状阻害剤
JP2017246001A Active JP6360961B2 (ja) 2014-09-12 2017-12-22 カテプシンcのスピロ環状阻害剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017246001A Active JP6360961B2 (ja) 2014-09-12 2017-12-22 カテプシンcのスピロ環状阻害剤

Country Status (34)

Country Link
US (3) US9540373B2 (enExample)
EP (2) EP3191487B1 (enExample)
JP (2) JP2017526716A (enExample)
KR (1) KR102510588B1 (enExample)
CN (2) CN108047240B (enExample)
AP (1) AP2017009733A0 (enExample)
AU (1) AU2015314355B2 (enExample)
BR (1) BR112017003433B1 (enExample)
CA (1) CA2960916C (enExample)
CL (1) CL2017000432A1 (enExample)
CO (1) CO2017002268A2 (enExample)
CY (1) CY1123033T1 (enExample)
DK (1) DK3191487T3 (enExample)
EA (1) EA031376B1 (enExample)
ES (1) ES2749009T3 (enExample)
HK (1) HK1255362A1 (enExample)
HR (1) HRP20191756T1 (enExample)
HU (1) HUE047208T2 (enExample)
IL (1) IL250262B (enExample)
LT (1) LT3191487T (enExample)
MX (2) MX378099B (enExample)
MY (1) MY188382A (enExample)
NZ (1) NZ728684A (enExample)
PE (1) PE20170438A1 (enExample)
PH (1) PH12017500453B1 (enExample)
PL (1) PL3191487T3 (enExample)
PT (1) PT3191487T (enExample)
RS (1) RS59444B1 (enExample)
SA (1) SA517381064B1 (enExample)
SG (1) SG11201701633SA (enExample)
SI (1) SI3191487T1 (enExample)
TW (1) TWI687424B (enExample)
UA (1) UA118610C2 (enExample)
WO (1) WO2016038007A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011116282A2 (en) 2010-03-19 2011-09-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Nicotinic acetylcholine receptor agonists
NO2699580T3 (enExample) 2014-01-24 2018-02-24
WO2016016242A1 (en) * 2014-08-01 2016-02-04 Boehringer Ingelheim International Gmbh Substituted oxetanes and their use as inhibitors of cathepsin c
AU2015314355B2 (en) 2014-09-12 2019-06-20 Boehringer Ingelheim International Gmbh Spirocyclic inhibitors of Cathepsin C
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
WO2018162312A1 (en) * 2017-03-10 2018-09-13 Basf Se Spirocyclic derivatives
JP2021512904A (ja) * 2018-02-07 2021-05-20 インスメッド インコーポレイテッド Anca関連血管炎の治療のためのある種の(2s)−n−[(1s)−1−シアノ−2−フェニル]−1,4−オキサゼパン−2−カルボキサミド
SI3758708T1 (sl) 2018-03-01 2025-04-30 Astrazeneca Ab Farmacevtski sestavki, ki vsebujejo (2S)-{(1S)-1-ciano-2-[4-(3-metil-2-okso-2,3-dihidro-1,3-benzoksazol-5-il)fenil]etil}-1,4-oksazepan-2-karboksamid
AU2019306532A1 (en) 2018-07-17 2021-03-04 Insmed Incorporated Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating Lupus Nephritis
CN110256429B (zh) * 2019-06-17 2021-06-22 广东药科大学 一种具有螺环结构的氨基嘧啶类化合物及其制备方法和应用
CN110257504A (zh) * 2019-06-30 2019-09-20 中南大学 一种难治性哮喘检测标记物的筛选方法及其应用
CN116157687A (zh) 2020-07-20 2023-05-23 英斯梅德股份有限公司 用于提取嗜中性粒细胞丝氨酸蛋白酶以及治疗二肽基肽酶1介导的病症的方法
CN114106005B (zh) * 2020-08-26 2025-08-01 西藏海思科制药有限公司 一种作为二肽基肽酶1抑制剂的腈衍生物及其用途
IL302872A (en) * 2020-11-17 2023-07-01 Vertex Pharma Solid forms of 4-(5-(4-fluorophenyl)-6-tetrahydro-2h-pyran-4-yl)- 1,5-dihydropyrrolo[2,3-f]indazol-7-yl)benzoic acid
CA3199568A1 (en) * 2020-12-04 2022-06-09 Reistone Biopharma Company Limited Small molecule inhibitor of cathepsin c and medicinal use thereof
CN114591315A (zh) * 2020-12-04 2022-06-07 瑞石生物医药有限公司 一种组织蛋白酶c小分子抑制剂
CN119317620A (zh) * 2022-06-13 2025-01-14 亚力维克希斯股份有限公司 氮杂环烷基羰基环状胺化合物
WO2024008680A1 (en) 2022-07-06 2024-01-11 Chiesi Farmaceutici S.P.A. Azetidine derivatives and use thereof as dipeptidyl peptidase 1 inhibitors
WO2024088307A1 (zh) * 2022-10-26 2024-05-02 上海壹迪生物技术有限公司 一种新型肽基腈类化合物及其应用
WO2024148308A1 (en) 2023-01-06 2024-07-11 Insmed Incorporated Novel, reversible dpp1 inhibitors and uses thereof
WO2025214464A1 (en) * 2024-04-12 2025-10-16 Insmed Incorporated Crystalline forms of (s) -n- (1-cyano-2- (2-fluoro-4- (1' - (oxetan-3-yl) -3h-spiro [isobenzofuran-1, 4' -piperidin] -6-yl) phenyl) ethyl) -2-azabicyclo [2.2.2] octane-1-carboxamide

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4125727A (en) 1976-10-18 1978-11-14 American Cyanamid Company Method of preparing imidazoisoindolediones
GB8922355D0 (en) 1989-10-04 1989-11-22 British Telecomm Sealing gland
GEP20012487B (en) 1998-09-16 2001-07-25 Merab Lomia Use of Chemical Agent 5-carbarnoyl-5H-Dibenz (b,f) azepin, its Derivatives and Analogues by New Purpose
US6960597B2 (en) 2000-06-30 2005-11-01 Orth-Mcneil Pharmaceutical, Inc. Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists
JP4365094B2 (ja) 2001-03-02 2009-11-18 メルク フロスト カナダ リミテツド カテプシンシステインプロテアーゼ阻害薬
TW200306189A (en) 2002-03-21 2003-11-16 Merz Pharma Gmbh & Co Kgaa Azabicyclic, azatricyclic and azaspirocyclic derivatives of aminocyclohexane NMDA, 5HT3, and neuronal nicotinic receptor antagonists
WO2004110988A1 (en) 2003-06-18 2004-12-23 Prozymex A/S Protease inhibitors
TW200528440A (en) 2003-10-31 2005-09-01 Fujisawa Pharmaceutical Co 2-cyanopyrrolidinecarboxamide compound
WO2006096807A1 (en) 2005-03-08 2006-09-14 Janssen Pharmaceutica N.V. Aza-bridged-bicyclic amino acid derivatives as alpha 4 integrin antagonists
RU2478620C2 (ru) * 2006-06-01 2013-04-10 Санофи-Авентис Спироциклические нитрилы в качестве ингибиторов протеазы
EP2072519A4 (en) 2006-09-28 2009-10-21 Banyu Pharma Co Ltd DIARYLKETIMINDERIVAT
JP5240201B2 (ja) 2007-10-12 2013-07-17 富士通株式会社 Ip電話自動試験システム及び方法
WO2009074829A1 (en) 2007-12-12 2009-06-18 Astrazeneca Ab Peptidyl nitriles and use thereof as dipeptidyl peptidase i inhibitors
WO2010128324A1 (en) 2009-05-07 2010-11-11 Astrazeneca Ab Substituted 1-cyanoethylheterocyclylcarboxamide compounds 750
WO2010142985A1 (en) 2009-06-10 2010-12-16 Astrazeneca Ab Substituted n-[1-cyano-2-(phenyl)ethyl]piperidin-2-ylcarboxmide compounds 761
WO2012119941A1 (en) 2011-03-04 2012-09-13 Prozymex A/S Peptidyl nitrilcompounds as peptidase inhibitors
US8999975B2 (en) * 2011-09-19 2015-04-07 Boehringer Ingelheim International Gmbh Substituted N- [1-cyano-2- (phenyl) ethyl] -2-azabicyclo [2.2.1] heptane-3-carboxamide inhibitors of cathepsin C
US9428452B2 (en) 2012-04-27 2016-08-30 Glaxo Group Limited Compounds
US9056874B2 (en) 2012-05-04 2015-06-16 Novartis Ag Complement pathway modulators and uses thereof
HK1209100A1 (en) 2012-05-22 2016-03-24 基因泰克有限公司 N-substituted benzamides and their use in the treatment of pain
US8859774B2 (en) 2012-05-25 2014-10-14 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
JO3459B1 (ar) 2012-09-09 2020-07-05 H Lundbeck As تركيبات صيدلانية لعلاج مرض الزهايمر
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
CA2886495C (en) 2012-09-28 2023-09-19 Ignyta, Inc. Azaquinazoline inhibitors of atypical protein kinase c
JP2015533134A (ja) * 2012-10-09 2015-11-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 錠剤の機械的安定性に適切な少なくとも1種の水和物形成活性物質及び/又はアジュバントを含有する機械的に安定な錠剤、特にアルギニン含有錠剤の製造における選択的に水分調整された打錠材料の使用
JP6461802B2 (ja) 2012-10-15 2019-01-30 エピザイム,インコーポレイティド 置換ベンゼン化合物
SG11201502369XA (en) 2012-10-16 2015-05-28 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of ror-gamma-t
NZ707495A (en) 2012-11-01 2019-01-25 Incyte Holdings Corp Tricyclic fused thiophene derivatives as jak inhibitors
US9233974B2 (en) 2012-12-21 2016-01-12 Gilead Sciences, Inc. Antiviral compounds
SG11201504946VA (en) 2012-12-21 2015-07-30 Quanticel Pharmaceuticals Inc Histone demethylase inhibitors
DK2935248T3 (en) 2012-12-21 2018-04-23 Plexxikon Inc RELATIONS AND PROCEDURE FOR CHINESE MODULATION AND INDICATIONS THEREOF
EP2953457B1 (en) 2013-02-08 2020-04-08 Celgene CAR LLC Erk inhibitors and uses thereof
JP6218860B2 (ja) 2013-03-14 2017-10-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング カテプシンcの置換2−アザ−ビシクロ[2.2.1]ヘプタン−3−カルボン酸(ベンジル−シアノ−メチル)−アミド阻害剤
AR095426A1 (es) 2013-03-14 2015-10-14 Onyx Therapeutics Inc Inhibidores tripeptídicos de la epoxicetona proteasa
EP2970252B1 (en) * 2013-03-14 2020-06-03 Boehringer Ingelheim International GmbH Substituted 2-aza-bicyclo[2.2.2]octane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c
EP3366678A1 (en) 2013-03-14 2018-08-29 Newlink Genetics Corporation Tricyclic compounds as inhibitors of immunosuppression mediated by tryptophan metabolization
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
MX355945B (es) 2013-03-14 2018-05-07 Novartis Ag 3-pirimidin-4-il-oxazolidin-2-onas como inhibidoras de idh mutante.
JO3383B1 (ar) 2013-03-14 2019-03-13 Lilly Co Eli مثبطات cdc7
US20140275082A1 (en) 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
TWI599567B (zh) 2013-03-14 2017-09-21 健生藥品公司 P2x7調節劑
JP6330058B2 (ja) * 2014-04-29 2018-05-23 ケアベイ・ヨーロッパ・リミテッドCarebay Europe Limited 針の挿入深さを調節する装置
US20160001608A1 (en) 2014-07-03 2016-01-07 Bridgestone Americas Tire Operations, Llc Sidewall decoration on rim guard
AU2015314355B2 (en) * 2014-09-12 2019-06-20 Boehringer Ingelheim International Gmbh Spirocyclic inhibitors of Cathepsin C
BR112017004580A2 (pt) 2014-09-12 2018-01-23 GlaxoSmithKline Intellectual Property composto, composição farmacêutica, produto de combinação, uso de um composto ou sal farmaceuticamente aceitável, e, método de tratamento.
AR101696A1 (es) 2014-09-12 2017-01-04 Lilly Co Eli Compuestos de azetidiniloxifenilpirrolidina
UY36294A (es) 2014-09-12 2016-04-29 Novartis Ag Compuestos y composiciones como inhibidores de quinasa

Similar Documents

Publication Publication Date Title
JP2017526716A5 (enExample)
JP2017522352A5 (enExample)
JP2016516020A5 (enExample)
JP2016510785A5 (enExample)
JP2018518537A5 (enExample)
JP2015521167A5 (enExample)
HRP20191756T1 (hr) Spirociklički inhibitori katepsina c
JP2016515110A5 (enExample)
JP2017528507A5 (enExample)
JP2016510784A5 (enExample)
JP2015524807A5 (enExample)
JP2013508279A5 (enExample)
JP2019529541A5 (enExample)
CN110769824B (zh) 用于治疗和/或预防细菌继发性感染的il-8抑制剂
CN102655859A (zh) 病毒感染的组合疗法治疗
JP2011507879A5 (enExample)
JP2013500977A5 (enExample)
JP2017522300A5 (enExample)
JP2017522350A5 (enExample)
RU2019111421A (ru) Способы лечения острого повреждения почек
JP2019533660A5 (enExample)
KR20180074654A (ko) 바이러스 감염의 치료를 위한 조성물 및 방법
RU2011147186A (ru) 2, 5-дизамещенные арилсульфонамидные антагонисты ссr3
JP2017522349A5 (enExample)
UY30935A1 (es) Combinacion:-antagonista del receptor de quimioquina 1 (ccr1) -agonista del receptor de glucocorticoides- opcionalmente agonista b(beta)2, -composicion farmacéutica conteniéndola -aplicaciones.